Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge
Por:
M. BOTELLO-MARABOTTO, J. TARRASO, A. MULET, L. PRESA-FERNANDEZ, E. FERNANDEZ-FABRELLAS, J. PORTAL, J. ROS, D. LOZANO-VICENTE, A. BERNARDOS, M. MARTINEZ-BISBAL, R. MARTINEZ-MANEZ and J. SIGNES-COSTA
Publicada:
1 mar 2025
Resumen:
Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (& boxH;CH-CH2-CH & boxH;) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19.
Filiaciones:
M. BOTELLO-MARABOTTO:
Univ Politecn Valencia, Unidad Mixta Invest Nanomed & Sensores, Inst Invest Sanitaria La Fe IISLAFE, Valencia, Spain
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
J. TARRASO:
Univ Valencia, Hosp Clin, Pulm Dept, INCLIVA, Valencia, Spain
A. MULET:
Univ Valencia, Hosp Clin, Pulm Dept, INCLIVA, Valencia, Spain
L. PRESA-FERNANDEZ:
Univ Valencia, Hosp Clin, Pulm Dept, INCLIVA, Valencia, Spain
E. FERNANDEZ-FABRELLAS:
Hosp Gen Valencia, Pulm Dept, Valencia, Spain
J. PORTAL:
Univ Seville, Hosp Virgen Rocio, Seville, Spain
J. ROS:
Hosp Virgen Arrixaca, Pulm Dept, Murcia, Spain
D. LOZANO-VICENTE:
Hosp Arcos Mar del Menor, Pulm Dept, Murcia, Spain
:
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
Univ Politecn Valencia, Dept Quim, Valencia, Spain
Univ Politecn Valencia, Ctr Invest Principe Felipe, Unidad Mixta UPV CIPF Invest Mecanismos Enfermedad, Valencia, Spain
:
Univ Politecn Valencia, Unidad Mixta Invest Nanomed & Sensores, Inst Invest Sanitaria La Fe IISLAFE, Valencia, Spain
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
Univ Valencia, Dept Quim Fis, Valencia, Spain
:
Univ Politecn Valencia, Unidad Mixta Invest Nanomed & Sensores, Inst Invest Sanitaria La Fe IISLAFE, Valencia, Spain
Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Reconocimiento Mol & Desarro, Valencia, Spain
Inst Salud Carlos III, CIBER Bioingn Biomat & Nanomed, Madrid, Spain
Univ Politecn Valencia, Dept Quim, Valencia, Spain
Univ Politecn Valencia, Ctr Invest Principe Felipe, Unidad Mixta UPV CIPF Invest Mecanismos Enfermedad, Valencia, Spain
J. SIGNES-COSTA:
Univ Valencia, Hosp Clin, Pulm Dept, INCLIVA, Valencia, Spain
hybrid
|